JNJ Johnson & Johnson

FINAL DEADLINE ALERT: Brower Piven Reminds Shareholders Of Approaching Deadline In Class Action Lawsuit And Encourages Investors Who Have Losses In Excess Of $100,000 From Investment In Johnson & Johnson To Contact The Firm

The securities litigation law firm of Brower Piven, A Professional Corporation, announces that a class action lawsuit has been commenced in the United States District Court for the District of New Jersey on behalf of purchasers of Johnson & Johnson (NYSE: JNJ) (“JNJ” or the “Company”) securities during the period between February 22, 2013 and February 7, 2018, inclusive (the “Class Period”). Investors who wish to become proactively involved in the litigation have until April 9, 2018 to seek appointment as lead plaintiff.

If you wish to choose counsel to represent you and the class, you must apply to be appointed lead plaintiff and be selected by the Court. The lead plaintiff will direct the litigation and participate in important decisions including whether to accept a settlement for the class in the action. The lead plaintiff will be selected from among applicants claiming the largest loss from investment in JNJ securities during the Class Period. Members of the class will be represented by the lead plaintiff and counsel chosen by the lead plaintiff. No class has yet been certified in the above action.

The complaint accuses the defendants of violations of the Securities Exchange Act of 1934 by virtue of the defendants’ failure to disclose during the Class Period that JNJ has known for decades that its talc products include asbestos fibers and that the exposure to those fibers can cause ovarian cancer and mesothelioma.

According to the complaint, following a September 21, 2017 article stating that documents indicate that JNJ had known for decades that its talc products include asbestos fibers and that the exposure to those fibers can cause ovarian cancer, and a February 5, 2018 report that court proceedings could expose potentially damaging documents in connection with JNJ’s talc products, the value of JNJ shares declined significantly.

If you have suffered a loss in excess of $100,000 from investment in JNJ securities purchased on or after February 22, 2013 and held through the revelation of negative information during and/or at the end of the Class Period and would like to learn more about this lawsuit and your ability to participate as a lead plaintiff, without cost or obligation to you, please contact Brower Piven either by email at [email protected] or by telephone at (410) 415-6616.

Attorneys at Brower Piven have extensive experience in litigating securities and other class action cases and have been advocating for the rights of shareholders since the 1980s. If you choose to retain counsel, you may retain Brower Piven without financial obligation or cost to you, or you may retain other counsel of your choice. You need take no action at this time to be a member of the class.

EN
01/04/2018

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Johnson & Johnson

Johnson & Johnson: Update following ratings affirmation

Our credit view of this issuer reflects its strong global scale and diversity and conservative financial policies, offset by unresolved talc litigation exposures.

Moody's Ratings affirms J&J's Aaa ratings; stable outlook

Moody's Ratings (Moody's) affirmed the ratings of Johnson & Johnson ("J&J") including the Aaa long-term issuer rating, Aaa senior unsecured rating, (P)Aaa senior unsecured medium term note program rating and Prime-1 commercial paper rating. The outlook remains stable. This rating action follows th...

Johnson & Johnson: 1 director

A director at Johnson & Johnson sold 8,891 shares at 162.160USD and the significance rating of the trade was 79/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clear...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch